US.VTRS · Viatris

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.4,
      "details": {
        "atrPct": 2.903648802736602,
        "turnoverUsdM": 132.4379625,
        "liquidityPoints": 0.4,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.VTRS",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 16.5214,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 2,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 5.8,
      "take_profit_price": 18.5561,
      "target_multiplier": 1.9,
      "technical_strength": 1.58,
      "take_profit_percent": 5.8
    },
    "positionPoints": 1.4,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 5.807297605473204,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 59,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 56,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 3
  },
  "market": {
    "ma20": 17.442,
    "ma50": 16.9322,
    "close": 17.54,
    "prevClose": 17.64,
    "avgVolume20": 9338041,
    "volumeRatio": 0.81,
    "changePercent": -0.57
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 3,
    "details": {
      "ret_5d": -0.004540295119182858,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 3,
      "vcp_bonus": 0,
      "vol_ratio": 0.8108597892476005,
      "ret_points": 0,
      "vol_points": 0,
      "range_ratio": 0.5656600574505322,
      "volat_points": 0,
      "day_range_pct": 0.014823261117445726,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 59,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.3,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 46,
        "contribution": 2.3
      },
      {
        "raw": 11.6,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 58,
        "contribution": 11.6
      },
      {
        "raw": 11.8,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 78.67,
        "contribution": 11.8
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.6,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 66,
        "contribution": 6.6
      },
      {
        "raw": 19.7,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 65.67,
        "contribution": 19.7
      },
      {
        "raw": 2,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 20,
        "contribution": 2
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "觀望",
    "result": 56,
    "details": [
      "基本面分析總分: 2.3/5分",
      "資金流分析總分: 11.6/20分",
      "市場環境分析總分: 11.8/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.6/10分",
      "技術信號分析總分: 19.7/30分",
      "情緒分析: 2/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.3,
      "資金流": 11.6,
      "市場環境": 11.8,
      "情緒分析": 2,
      "技術信號": 19.7,
      "風險管理": 6.6
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 7,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.5,
          "pePoints": 0,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.4,
          "marginPoints": 0,
          "turnoverUsdM": 132.4379625,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.4,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 1.6,
          "mfiPoints": 3.2,
          "obvPoints": 0.8,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.VTRS",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "良好",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 14.84
            }
          },
          "trend": {
            "score": 4,
            "details": {
              "qqq": {
                "ma20": 739.38449965,
                "ma50": 725.6844004000002,
                "name": "QQQ",
                "close": 746.039978,
                "points": 2
              },
              "spy": {
                "ma20": 768.8379970499998,
                "ma50": 768.1957967800001,
                "name": "SPY",
                "close": 778.099976,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.903648802736602,
          "atrPoints": 3,
          "cciPoints": 2.4,
          "vixPoints": 2.4,
          "marketTrendPoints": 4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 7,
              "negativeHits": 1,
              "positiveHits": 1,
              "sentimentScoreRaw": 0
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 142749764,
                "url": "https://finnhub.io/api/news?id=f625620a5166e2294c6ffca2d3e568afb21bd4e2762fca9ab49ce4dea3d1dc67",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris (VTRS) has brought renewed attention to its stock after agreeing to buy Pacira BioSciences in a US$1.65 billion all-cash deal, adding two patent-protected non-opioid pain medicines to its portfolio. Viatris shares trade at US$17.44, and the stock has logged a 5.0% 1 month share price return and a 7.2% 3 month share price return. The year to date share price return of 40.0% pairs with a 1 year total shareholder return of 80.8%, which hints that investors have been reassessing both its...",
                "category": "company",
                "datetime": 1791526186,
                "headline": "Viatris (VTRS) Buys Pacira As Fair Value Stays In Focus"
              },
              {
                "id": 142734359,
                "url": "https://finnhub.io/api/news?id=3e22f5fe5abd26c055cc99d0ed51840b462dd7bd4d5a8c517dd2cd0ecff1f9ad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris Inc. (NASDAQ:VTRS) and Opus Genetics, Inc. (NASDAQ:IRD) are waiting on the same decision. By October 17, the FDA is due to rule on MR-141, an eye drop known as phentolamine 0.75%, as a treatment for presbyopia, the age-related loss of near focus. The application leans on two successful late-stage trials, VEGA-2 and VEGA-3, and […]",
                "category": "company",
                "datetime": 1791500135,
                "headline": "Could an FDA Nod for MR-141 Give Viatris (VTRS) and Opus Genetics (IRD) a Presbyopia Payoff?"
              },
              {
                "id": 142732301,
                "url": "https://finnhub.io/api/news?id=2d4c0cb7d3d7513aae0db45d49d4636e4abc09221c50fcb38939e7ec4d9ea5bf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris (NasdaqGS: VTRS) announced an agreement to acquire Pacira BioSciences, expanding its presence in non-opioid pain therapies. The deal brings Pacira's portfolio of non-opioid pain management products under Viatris, broadening its branded medicines offerings. The transaction targets a larger role for Viatris in post-surgical and acute pain treatment that does not rely on traditional opioids. The Pacira BioSciences acquisition reshapes Viatris' pain-therapy portfolio, which investors may...",
                "category": "company",
                "datetime": 1791482925,
                "headline": "Why Is Viatris (VTRS) Expanding Its Non Opioid Pain Portfolio Now?"
              },
              {
                "id": 142666020,
                "url": "https://finnhub.io/api/news?id=55194c0f1c0603e6c25879ac3c2430a56cc34f1d5bfaed7b44cbca45bb7e4c52",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "VTRS vs. AVTR: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1791297605,
                "headline": "VTRS vs. AVTR: Which Stock Is the Better Value Option?"
              },
              {
                "id": 142663464,
                "url": "https://finnhub.io/api/news?id=4f311227dfa37e1ccb4af6f1808018d8048fb6ed53f3f1422af61ec01aaa2511",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
                "category": "company",
                "datetime": 1791290405,
                "headline": "Should Value Investors Buy Viatris (VTRS) Stock?"
              },
              {
                "id": 142634107,
                "url": "https://finnhub.io/api/news?id=d369cb650069dcab5fb8c43d6daff031243caea528802db0b0b1c49b4a1eaf0c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Roche has two FDA catalysts coming up for Tecentriq and Enspryng, while Viatris and Opus Genetics await a decision on expanding MR-141 into the presbyopia market.",
                "category": "company",
                "datetime": 1791199313,
                "headline": "FDA Decision Watch: RHHBY, VTRS And IRD Face Key October Drug Rulings As MRK Withdraws Application"
              },
              {
                "id": 142298776,
                "url": "https://finnhub.io/api/news?id=ce05ca98726ae76cc7e548345343f33d22ebba5bfd7624adad01a86ce345f8bf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris Inc. (NASDAQ:VTRS) announced on September 16 that Japan’s Ministry of Health, Labour and Welfare approved WAKIX, or pitolisant, for narcolepsy and excessive daytime sleepiness associated with obstructive sleep apnea syndrome in patients receiving treatment for airway obstruction. The narcolepsy approval covers types 1 and 2, with and without cataplexy, or sudden muscle weakness. The […]",
                "category": "company",
                "datetime": 1789948981,
                "headline": "Viatris (VTRS) Wins Japan WAKIX Approval. Can it Build a Meaningful Specialty Business?"
              }
            ],
            "raw_source": [
              {
                "id": 142822104,
                "url": "https://finnhub.io/api/news?id=1b1cb537dc69a2ad384e49af6ff09d28cb8726744942df5d44ab44e6209b30ac",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2187870802/image_2187870802.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VTRS",
                "summary": "Viatris Q3 earnings preview: raised 2026 EPS guidance, improving margins, and Pacira acquisition impact.",
                "category": "company",
                "datetime": 1791807115,
                "headline": "Viatris: Is The Pacira Deal A Game Changer? (Rating Upgrade)"
              },
              {
                "id": 142812849,
                "url": "https://finnhub.io/api/news?id=7e3c3aa1f35b782329d258f4906ff8cb7efb85a8a71dce80cfe4f008f09e30ea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Wall Street is abuzz with deal chatter as major healthcare, beverage, and oil companies eye significant deals in the coming weeks.",
                "category": "company",
                "datetime": 1791786745,
                "headline": "Stocktwits M&A Watch: Viatris-Pacira Deal, Coca-Cola’s Costa Coffee Sale, Devon’s Eagle Ford Divestiture In Focus"
              },
              {
                "id": 142817235,
                "url": "https://finnhub.io/api/news?id=6636e9f3196863cafd7362e9c5d33d63bd7663bb0ef4c2812cd9230c8db543d1",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1162845770/image_1162845770.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VTRS",
                "summary": "Viatris has rebounded 50% YTD, driven by a return to growth and operating leverage after years of stagnation and execution issues. I rate the VTRS stock a hold.",
                "category": "company",
                "datetime": 1791786580,
                "headline": "Viatris: Improved Confidence Drives M&A Action Again"
              },
              {
                "id": 142771611,
                "url": "https://finnhub.io/api/news?id=d733ecca87bddd4bf3849907b5495fbcfde613e7b73fda30673e9657cfaec768",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Drugmakers this week did not purchase experimental drug candidates but invested in approved drugs and a factory that makes imaging agents.",
                "category": "company",
                "datetime": 1791594740,
                "headline": "Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights"
              },
              {
                "id": 142764368,
                "url": "https://finnhub.io/api/news?id=eb521e4f856e3e3f4a22d02a6383127fc5cd085e3dec8cf2cb3f55a0189ce270",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Pacira Biosciences' (PCRX) proposed acquisition by Viatris (VTRS) is not likely to see a superior bi",
                "category": "company",
                "datetime": 1791559407,
                "headline": "Pacira Biosciences' Acquisition by Viatris Unlikely to See Superior Bid, RBC Says"
              },
              {
                "id": 142791266,
                "url": "https://finnhub.io/api/news?id=92546e8c535001a9c91c7067dcd42374edac84cda7c9007070044664e3809f11",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/09/benzinga-deal-dispatch2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "VTRS",
                "summary": "Major M&A deals this week include Viatris buys Pacira BioSciences, TowneBank acquires blueharbor, Energy Transfer buys Vacquero Midstream.",
                "category": "company",
                "datetime": 1791558208,
                "headline": "Deal Dispatch: Uber Buys ezCater For $2.3B, Skydance Takes Over Warner Bros., True Food Kitchen Bankruptcy"
              },
              {
                "id": 142764369,
                "url": "https://finnhub.io/api/news?id=2c0ab1334d76195151a435b63cd5037292573e87cb646d93ebb8b2afe58ef06c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "VTRS is set to acquire PCRX for $1.65 billion in cash, adding two marketed pain therapies and a clinical-stage gene therapy candidate to expand its non-opioid pain portfolio.",
                "category": "company",
                "datetime": 1791553020,
                "headline": "Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio"
              },
              {
                "id": 139930306,
                "url": "https://finnhub.io/api/news?id=7c7bc27315adbe5bcfe5ed5e35cd4e6dcc9d016797069c983e56b5235fa1d71d",
                "image": "",
                "source": "Benzinga",
                "related": "VTRS",
                "summary": "",
                "category": "company",
                "datetime": 1791546303,
                "headline": "How Your Taxes Will Be Different Next Year, And Why You'll Have Trump To Thank"
              },
              {
                "id": 142759478,
                "url": "https://finnhub.io/api/news?id=bdf64b92cceb258d4c0237d268ed8fc857f6eee89dbbe5f287ce386653490db3",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1140380523/image_1140380523.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VTRS",
                "summary": "Viatris is acquiring Pacira Biosciences to boost its pain management portfolio and address revenue stagnation. Read why VTRS stock is upgraded to a hold.",
                "category": "company",
                "datetime": 1791531022,
                "headline": "Viatris To Acquire Pacira BioSciences: What Investors Should Know"
              },
              {
                "id": 142757986,
                "url": "https://finnhub.io/api/news?id=24ea463298c1eac35a6ce9c7ee6d80b1b7ea180b88505ce7b65c36a37b4d91b1",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220219831/image_1220219831.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VTRS",
                "summary": "October 2026 dividend dogs: 84 picks screened by yield + free cash flow safety.",
                "category": "company",
                "datetime": 1791529421,
                "headline": "Buy Any Of 15 Ideal 'Safer' October Dogs Tenured Over 10 Years"
              },
              {
                "id": 142749764,
                "url": "https://finnhub.io/api/news?id=f625620a5166e2294c6ffca2d3e568afb21bd4e2762fca9ab49ce4dea3d1dc67",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris (VTRS) has brought renewed attention to its stock after agreeing to buy Pacira BioSciences in a US$1.65 billion all-cash deal, adding two patent-protected non-opioid pain medicines to its portfolio. Viatris shares trade at US$17.44, and the stock has logged a 5.0% 1 month share price return and a 7.2% 3 month share price return. The year to date share price return of 40.0% pairs with a 1 year total shareholder return of 80.8%, which hints that investors have been reassessing both its...",
                "category": "company",
                "datetime": 1791526186,
                "headline": "Viatris (VTRS) Buys Pacira As Fair Value Stays In Focus"
              },
              {
                "id": 142734359,
                "url": "https://finnhub.io/api/news?id=3e22f5fe5abd26c055cc99d0ed51840b462dd7bd4d5a8c517dd2cd0ecff1f9ad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris Inc. (NASDAQ:VTRS) and Opus Genetics, Inc. (NASDAQ:IRD) are waiting on the same decision. By October 17, the FDA is due to rule on MR-141, an eye drop known as phentolamine 0.75%, as a treatment for presbyopia, the age-related loss of near focus. The application leans on two successful late-stage trials, VEGA-2 and VEGA-3, and […]",
                "category": "company",
                "datetime": 1791500135,
                "headline": "Could an FDA Nod for MR-141 Give Viatris (VTRS) and Opus Genetics (IRD) a Presbyopia Payoff?"
              },
              {
                "id": 142732299,
                "url": "https://finnhub.io/api/news?id=4983ec76756a35e64873863728a2435deff312c722d2a4d1822b3c1d3bdab976",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Healthcare stocks were lower late Thursday afternoon, with the NYSE Healthcare Index shedding 0.6% a",
                "category": "company",
                "datetime": 1791489205,
                "headline": "Sector Update: Healthcare Stocks Softer Late Afternoon"
              },
              {
                "id": 142732300,
                "url": "https://finnhub.io/api/news?id=0299a2e351840357a1bfb73b04b03a1352ee8fb86d31168b510340d60c2772a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "The deal, at $36.50 per share, represents a roughly 45% premium and is expected to close by the end of 2026",
                "category": "company",
                "datetime": 1791484284,
                "headline": "Viatris to acquire Pacira BioSciences for $1.65 billion"
              },
              {
                "id": 142732301,
                "url": "https://finnhub.io/api/news?id=2d4c0cb7d3d7513aae0db45d49d4636e4abc09221c50fcb38939e7ec4d9ea5bf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris (NasdaqGS: VTRS) announced an agreement to acquire Pacira BioSciences, expanding its presence in non-opioid pain therapies. The deal brings Pacira's portfolio of non-opioid pain management products under Viatris, broadening its branded medicines offerings. The transaction targets a larger role for Viatris in post-surgical and acute pain treatment that does not rely on traditional opioids. The Pacira BioSciences acquisition reshapes Viatris' pain-therapy portfolio, which investors may...",
                "category": "company",
                "datetime": 1791482925,
                "headline": "Why Is Viatris (VTRS) Expanding Its Non Opioid Pain Portfolio Now?"
              },
              {
                "id": 142731289,
                "url": "https://finnhub.io/api/news?id=75b408213592aa8c432b82237f100a25d462a8b31fcaeef3b3acc0babd4fecf4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Pacira BioSciences secured a $1.65 billion buyout deal with Viatris, while Haemonetics expanded its CSL Plasma partnership, prompting BTIG to raise its price target.",
                "category": "company",
                "datetime": 1791481701,
                "headline": "HAE, PCRX Stocks Hit Multi-Year Highs Amid Broader Market Selloff – What’s Driving The Momentum Today?"
              },
              {
                "id": 142730997,
                "url": "https://finnhub.io/api/news?id=432e0925ebab3aeb2ff78568017b127382217a73fb75460d7f75b5111e5a2c09",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris has agreed to acquire Pacira BioXciences, acquiring its portfolio of non-opioid pain medications.",
                "category": "company",
                "datetime": 1791480540,
                "headline": "Why Pacira BioSciences Stock Is Having Its Best Day Ever After $1.7 Billion Viatris Acquisition"
              },
              {
                "id": 142731287,
                "url": "https://finnhub.io/api/news?id=c3ce653013b29b379ed4a5737261a5424a55939cb3cb0060b60fdb4293025995",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "The non-opioid pain space is attracting increasing attention as experts sound the alarm on dependency issues linked to long-term opioid-based pain management.",
                "category": "company",
                "datetime": 1791480016,
                "headline": "Viatris makes foray into non-opioid pain space on $1.65bn Pacira buyout"
              },
              {
                "id": 142731288,
                "url": "https://finnhub.io/api/news?id=fa0b1bb101e0dd819659eeae527fbd504b5fb20939171e932a16dfde88959762",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris (VTRS) will acquire Pacira BioSciences (PCRX) in an all-cash deal worth roughly $1.65 billio",
                "category": "company",
                "datetime": 1791475369,
                "headline": "Viatris Agrees to Acquire Pacira BioSciences in $1.65 Billion Deal"
              },
              {
                "id": 142730119,
                "url": "https://finnhub.io/api/news?id=1acd7c6506a155c5216be2b4d4e38c32fc8c22700a12b8bc2faeb81ddb5faf0b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "The deal hands Viatris two non-opioid pain treatments that booked nearly $700 million in 2025 but could soon lose patent protection. Viatris vowed to use its “intellectual property expertise” to sustain sales.",
                "category": "company",
                "datetime": 1791475200,
                "headline": "Viatris boosts pain drug portfolio with $1.7B buyout of Pacira"
              },
              {
                "id": 142729671,
                "url": "https://finnhub.io/api/news?id=9fd60e42589b1f6881f6a8d9fcb73b4e2b1940ac5916d2e73afd6b48966c8498",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "The specialty pharmaceutical company is being acquired.",
                "category": "company",
                "datetime": 1791473583,
                "headline": "Why Pacira BioSciences Skyrocketed Today"
              },
              {
                "id": 142730120,
                "url": "https://finnhub.io/api/news?id=3236b408568abce0e42115083b4ed388e5e2574694b55b0850c6874e70b1d18c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "PCRX and REI are drawing attention from put traders",
                "category": "company",
                "datetime": 1791473005,
                "headline": "2 Stocks Drawing Bearish Options Activity Today"
              },
              {
                "id": 142730121,
                "url": "https://finnhub.io/api/news?id=30b113fb9a0b5d7ab00a88df55bad5bae68e070842d75dd1df6d3b3279d97197",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris pledged Thursday to buy small biotech company Pacira Biosciences for $1.65 billion, sending Pacira stock skyrocketing.",
                "category": "company",
                "datetime": 1791472540,
                "headline": "Pacira Biosciences Snags $1.65 Billion Viatris Takeover Deal; Shares Fly"
              },
              {
                "id": 142730122,
                "url": "https://finnhub.io/api/news?id=43101eba50b2619a76eba2f111be0b512cf170f7bbda90307441cd1fdf38de58",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "The $36. 50-per-share cash acquisition adds two established pain treatments to Viatris’ portfolio and is expected to contribute immediately to its financial guidance metrics following completion by the end of 2026.",
                "category": "company",
                "datetime": 1791470228,
                "headline": "Viatris Agrees to Acquire Pacira BioSciences for $1.65 Billion in Non-Opioid Pain Therapy Expansion"
              },
              {
                "id": 142762175,
                "url": "https://finnhub.io/api/news?id=98de6faa473c2f9127999113582d914d108211d1f157dc95e170627344028849",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/08/Merger-And-Acquisition-Business-Corporat.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "VTRS",
                "summary": "Pacira BioSciences stock surges 44% after Viatris announces a $1.65 billion takeover deal to expand its pain treatment portfolio.",
                "category": "company",
                "datetime": 1791463795,
                "headline": "Viatris Bets Big on Non-Opioid Painkillers With Pacira Buyout"
              },
              {
                "id": 142726444,
                "url": "https://finnhub.io/api/news?id=1ac25b3729a281f22c541b2922f619ac20a7dd4de053fb7af5ccb6d5a18d03b1",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "VTRS",
                "summary": "Stay updated with the S&P500 stocks that are on the move in today's pre-market session.",
                "category": "company",
                "datetime": 1791462901,
                "headline": "These S&P500 stocks that are showing activity before the opening bell on Thursday."
              },
              {
                "id": 142726215,
                "url": "https://finnhub.io/api/news?id=15e6c4ad7bc73bb52c80b81169bc5f102bb447fa98e773a8746b9be2b92f750c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris Inc. (Nasdaq: VTRS), a global healthcare company, and Pacira BioSciences, Inc. (Nasdaq: PCRX), a leader in innovative non-opioid pain therapies, today announced that they have entered into a definitive agreement under which Viatris has agreed to acquire all of the outstanding shares of common stock of Pacira for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion.",
                "category": "company",
                "datetime": 1791459900,
                "headline": "Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies"
              },
              {
                "id": 142666020,
                "url": "https://finnhub.io/api/news?id=55194c0f1c0603e6c25879ac3c2430a56cc34f1d5bfaed7b44cbca45bb7e4c52",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "VTRS vs. AVTR: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1791297605,
                "headline": "VTRS vs. AVTR: Which Stock Is the Better Value Option?"
              },
              {
                "id": 142663464,
                "url": "https://finnhub.io/api/news?id=4f311227dfa37e1ccb4af6f1808018d8048fb6ed53f3f1422af61ec01aaa2511",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
                "category": "company",
                "datetime": 1791290405,
                "headline": "Should Value Investors Buy Viatris (VTRS) Stock?"
              },
              {
                "id": 142664260,
                "url": "https://finnhub.io/api/news?id=709e8b1d30dac0baf5eef775364bb4bb07d28957b51c222652a5e125a2fc877d",
                "image": "",
                "source": "Benzinga",
                "related": "VTRS",
                "summary": "UBS  analyst Ashwani Verma   maintains Viatris (NASDAQ:VTRS) with a Buy and raises the price target from $23 to $26.",
                "category": "company",
                "datetime": 1791218613,
                "headline": "UBS Maintains Buy on Viatris, Raises Price Target to $26"
              },
              {
                "id": 142634107,
                "url": "https://finnhub.io/api/news?id=d369cb650069dcab5fb8c43d6daff031243caea528802db0b0b1c49b4a1eaf0c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Roche has two FDA catalysts coming up for Tecentriq and Enspryng, while Viatris and Opus Genetics await a decision on expanding MR-141 into the presbyopia market.",
                "category": "company",
                "datetime": 1791199313,
                "headline": "FDA Decision Watch: RHHBY, VTRS And IRD Face Key October Drug Rulings As MRK Withdraws Application"
              },
              {
                "id": 142634108,
                "url": "https://finnhub.io/api/news?id=1df829ad6224d3a3f160a5566995f8233caa8abe3b47da97b8998ce107e4ad5e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatment Option to Harrow’s Growing Ocular Surface FranchiseNASHVILLE, Tenn., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has closed its previously announced acquisition of TYRVAYA® (varenicline solution) nasal spray 0.03 mg from Viatris Inc., a global healthcare company. At closing, Harr",
                "category": "company",
                "datetime": 1791198000,
                "headline": "Harrow Closes Acquisition of TYRVAYA®"
              },
              {
                "id": 142633157,
                "url": "https://finnhub.io/api/news?id=586b2f1219601fd2bd21c4ddd0009007b298b50795cd71ba3fa32edbfdf1732a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report third-quarter 2026 financial results on Thursday, November 5, 2026. Company executives will host a conference call and live webcast at 8:30 a.m. ET on the same date to discuss results.",
                "category": "company",
                "datetime": 1791197940,
                "headline": "Viatris to Report Third-Quarter 2026 Financial Results on November 5, 2026"
              },
              {
                "id": 142519312,
                "url": "https://finnhub.io/api/news?id=f03ad3d7980bede2842ac49a00333d5e3526832ced52097dbbc0e4b1c0d29bcc",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2207938858/image_2207938858.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VTRS",
                "summary": "Aquestive Therapeutics offers a differentiated epinephrine product, Anaphylm, but faces pricing and market share headwinds. Learn why AQST stock is a hold.",
                "category": "company",
                "datetime": 1790763237,
                "headline": "Aquestive Therapeutics: The Market Is Already Pricing In Anaphylam's Success"
              },
              {
                "id": 142500609,
                "url": "https://finnhub.io/api/news?id=12f7531c1dfdfa68cba3d32333e571134adeaeece7758a8cbb5236184ba6091f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it was named to Forbes' World's Best Employers list for the sixth consecutive year. The ranking is presented by Forbes and Statista, the world-leading statistics portal and industry ranking provider, and is based on independent employee feedback collected globally, highlighting employee trust, workplace experience and organizational culture at Viatris.",
                "category": "company",
                "datetime": 1790704800,
                "headline": "Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year"
              },
              {
                "id": 142469836,
                "url": "https://finnhub.io/api/news?id=c12fd4505fe17fdad5ac70e1ca08de2c446637afd094d810b99c6d6f5a82993e",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "VTRS",
                "summary": "Curious about the S&P500 stocks that are in motion on Monday? Join us as we explore the top movers within the S&P500 index during today's session.",
                "category": "company",
                "datetime": 1790622301,
                "headline": "Stay informed with the top movers within the S&P500 index on Monday."
              },
              {
                "id": 142425662,
                "url": "https://finnhub.io/api/news?id=fba9adb4c6307cf46440f63540a7f3d5f1cf30273f1416ebeed91f4d83ae0290",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Investing.com -- Viatris filed a lawsuit against Novo Nordisk in Delaware federal court, requesting a determination that its planned generic version of Wegovy would not violate the Danish company's patent rights.",
                "category": "company",
                "datetime": 1790366007,
                "headline": "Viatris sues Novo Nordisk over generic Wegovy patent dispute"
              },
              {
                "id": 142385868,
                "url": "https://finnhub.io/api/news?id=bc3f9279ddd6c1a95bbb039fa092e924a69d56d00f2036883a2fc3ea4ce2b6ab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris has comfortably outperformed the broader S&P 500 over the past year, with analysts maintaining a fairly bullish outlook on the stock.",
                "category": "company",
                "datetime": 1790247430,
                "headline": "Is Viatris Stock Outperforming the S&P 500?"
              },
              {
                "id": 142361502,
                "url": "https://finnhub.io/api/news?id=bdcacbe8919995cd8b871e14b2d68aab2e5a9392e23d3633bf38481d0052e2a8",
                "image": "",
                "source": "Benzinga",
                "related": "VTRS",
                "summary": "Oppenheimer  analyst Les Sulewski   initiates coverage on Viatris (NASDAQ:VTRS) with a Outperform rating and announces Price Target of $25.",
                "category": "company",
                "datetime": 1790150706,
                "headline": "Oppenheimer Initiates Coverage On Viatris with Outperform Rating, Announces Price Target of $25"
              },
              {
                "id": 142359613,
                "url": "https://finnhub.io/api/news?id=1b7abf729ec551603288b65262b8c24463d1852740a42d2e937ea27d64754e73",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/23/Chandler--Arizona---April-08-2023cvs-Hea.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "VTRS",
                "summary": "Analysts review high-yield healthcare stocks CVS, Viatris and Medtronic, citing ratings, price targets, dividend yields and recent company news.",
                "category": "company",
                "datetime": 1790147106,
                "headline": "Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks Delivering High-Dividend Yields"
              },
              {
                "id": 142298776,
                "url": "https://finnhub.io/api/news?id=ce05ca98726ae76cc7e548345343f33d22ebba5bfd7624adad01a86ce345f8bf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris Inc. (NASDAQ:VTRS) announced on September 16 that Japan’s Ministry of Health, Labour and Welfare approved WAKIX, or pitolisant, for narcolepsy and excessive daytime sleepiness associated with obstructive sleep apnea syndrome in patients receiving treatment for airway obstruction. The narcolepsy approval covers types 1 and 2, with and without cataplexy, or sudden muscle weakness. The […]",
                "category": "company",
                "datetime": 1789948981,
                "headline": "Viatris (VTRS) Wins Japan WAKIX Approval. Can it Build a Meaningful Specialty Business?"
              },
              {
                "id": 142273044,
                "url": "https://finnhub.io/api/news?id=23d0de51b9583ba0bc7fe9173b78614467868725cd8b866b101ba10ec01b9084",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "A new US law that could slap tariffs of up to 100% on imports from big buyers of Russian energy, including India, suddenly puts long trusted trade routes in question and opens the door for alternative suppliers. That shift creates a potential opening for US-focused stocks exposed to this news, and investors who ignore it risk missing a meaningful realignment in global sourcing. This article examines the law’s potential ripple effects and highlights 3 stocks from the screener that could be...",
                "category": "company",
                "datetime": 1789838062,
                "headline": "3 US Stocks That Could Gain If Buyers Shift Away From India"
              },
              {
                "id": 142197168,
                "url": "https://finnhub.io/api/news?id=4ded9287680153405d14690cb18989c70c791fc2a8bd7ad575a7949ac7d765c8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Gilead Sciences (NASDAQ:GILD) has expanded six existing royalty-free voluntary licensing agreements to include an investigational once-yearly formulation of lenacapavir for HIV prevention, the company announced. The expanded agreements cover 120 countries with high HIV incidence, primarily low- and lower-middle-income nations.",
                "category": "company",
                "datetime": 1789566407,
                "headline": "Gilead Expands Lenacapavir Licensing Agreements to Include Once-Yearly HIV Prevention Formulation"
              },
              {
                "id": 142227126,
                "url": "https://finnhub.io/api/news?id=424da783644caf72eeb16f1f7ee06096d4f194d69f32c0158e77efdd6733d550",
                "image": "",
                "source": "Benzinga",
                "related": "VTRS",
                "summary": "Piper Sandler  analyst David Amsellem   maintains Viatris (NASDAQ:VTRS) with a Neutral and raises the price target from $12 to $13.",
                "category": "company",
                "datetime": 1789565516,
                "headline": "Piper Sandler Maintains Neutral on Viatris, Raises Price Target to $13"
              },
              {
                "id": 142194247,
                "url": "https://finnhub.io/api/news?id=e203dbba0dcc330fdc4ec70f010ae113203132ddd0bbc1a533b26c2ce2b4e643",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that Japan's Ministry of Health, Labour and Welfare has granted approval for WAKIX® (pitolisant) for the treatment of excessive daytime sleepiness (EDS) associated with obstructive sleep apnea syndrome (OSAS) in patients receiving treatment for airway obstruction, and approval for narcolepsy (type 1 and 2 – with and without cataplexy). WAKIX is the first histamine H3 receptor antagonist/inverse agonist approved in Japan fo",
                "category": "company",
                "datetime": 1789556340,
                "headline": "Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome"
              },
              {
                "id": 142196130,
                "url": "https://finnhub.io/api/news?id=f143f92a40278c622263b1c06a5de75fc154cd2b5196e524a4d62f3b3684531f",
                "image": "",
                "source": "Benzinga",
                "related": "VTRS",
                "summary": "Approval Addresses High Unmet Medical Need and Further Advances Viatris' Innovative Portfolio in JapanPITTSBURGH, Sept. 16, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today",
                "category": "company",
                "datetime": 1789542105,
                "headline": "Viatris Secures Japan Approval For WAKIX In Treating Excessive Daytime Sleepiness Linked To Sleep Apnea And Narcolepsy"
              },
              {
                "id": 142139504,
                "url": "https://finnhub.io/api/news?id=892ee473a89448e463e9ebabbdd3627fdd3c2e2cad825c716923497669bcd3f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VTRS",
                "summary": "From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 30% gain over the past six months, beating the S&P 500 by 16.7 percentage points.",
                "category": "company",
                "datetime": 1789399410,
                "headline": "3 Healthcare Stocks That Fall Short"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 7,
            "negative_hits": 1,
            "positive_hits": 1,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0,
            "source_article_count": 47,
            "discarded_article_count": 40
          },
          "sentimentPoints": 2
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 19.7,
        "grade": "一般",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 1.6,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1.6,
            "vcp_reason": "波幅收縮(13.2%→8.8%)；站上MA50；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 3,
              "vol_ref": 8844770,
              "down_days": 6,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 9812270,
              "avg_vol_20": 9311875,
              "avg_vol_30": 8844770,
              "range_pct_10": 0.08779931584948684,
              "range_pct_20": 0.11687571265678454,
              "range_pct_30": 0.13169897377423026,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": false,
              "up_expand_days": 0,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.1093866770984435,
              "dist_to_20d_high": 0.04829083016820405,
              "down_shrink_days": 2,
              "breakout_level_20d": 18.43,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.6666666666666667
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0.4,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 0.8
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.4,
            "details": {
              "atrPct": 2.903648802736602,
              "turnoverUsdM": 132.4379625,
              "liquidityPoints": 0.4,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.VTRS",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 16.5214,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 2,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 5.8,
            "take_profit_price": 18.5561,
            "target_multiplier": 1.9,
            "technical_strength": 1.58,
            "take_profit_percent": 5.8
          },
          "positionPoints": 1.4,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 5.807297605473204,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 85.71,
    "atr": {
      "atr": 0.5093,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.9
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "平衡",
      "score": 6,
      "value": 40.58
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "平衡",
      "score": 4,
      "value": 0.046
    },
    "kdj": {
      "d": 43.85,
      "j": 44.01,
      "k": 43.9,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "入貨中",
      "score": 8,
      "value": 62.05
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 2,
      "trend": "資金流出",
      "value": -35862325,
      "recentSlope": -3401202.5,
      "previousSlope": 2773280
    },
    "rsi": 56.77,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 18.2905,
      "position": "SAR喺價上",
      "distancePct": 4.28,
      "previousTrend": "下降"
    },
    "ma50": 16.9322,
    "macd": {
      "macd": 0.18955703867590756,
      "trend": "中性偏多",
      "signal": 0.21713388602232145,
      "histogram": -0.027576847346413885
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 17.4621,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 21
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "無力",
      "ratio": 0.81,
      "score": 4,
      "avgVolume": 9338041,
      "currentVolume": 7550625
    },
    "derived": {
      "ma20": 17.442,
      "ma50": 16.9322,
      "prevClose": 17.64,
      "avgVolume10": 9329633,
      "avgVolume20": 9338041,
      "changePercent": -0.57,
      "avgVolumeForScore": 9338041
    },
    "ma_cross": {
      "ma20": 17.442,
      "ma50": 16.9322,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 17.398,
      "prevMa50": 16.9326,
      "spreadPct": 3.01,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 16.6771,
      "upper": 18.2069,
      "position": "上半部"
    },
    "rsi_short": 44,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.81
    }
  }
}

{
  "close": 17.54,
  "volume": 7550625,
  "changePercent": -0.57
}